Evidence map›Paper›PMID 39693499›Full record

ArticleJournal of medicinal chemistry2025

Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives.

Anna M Schoepf, Maximilian Gebhart, Martin Federspiel, Isabel Heidegger, Martin Puhr, Madlen Hotze, Marcel Kwiatkowski, Andreas Pircher, Dominik Wolf, Sieghart Sopper and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna M SchoepfCCB - Centrum for Chemistry and Biomedicine, Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck 6020, Austria.
Maximilian GebhartCCB - Centrum for Chemistry and Biomedicine, Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0009-0004-2714-2647
Martin FederspielCCB - Centrum for Chemistry and Biomedicine, Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck 6020, Austria.
Isabel HeideggerDepartment of Urology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Martin PuhrDepartment of Urology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Madlen HotzeDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck 6020, Austria.
Marcel KwiatkowskiDepartment of Biochemistry and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0002-5804-6031
Andreas PircherDepartment of Internal Medicine V, Hematology and Oncology, Tyrolean Cancer Research Institute (TKFI), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck 6020, Austria.
Dominik WolfDepartment of Internal Medicine V, Hematology and Oncology, Tyrolean Cancer Research Institute (TKFI), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck 6020, Austria.
Sieghart SopperDepartment of Internal Medicine V, Hematology and Oncology, Tyrolean Cancer Research Institute (TKFI), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck 6020, Austria.
Ronald GustCCB - Centrum for Chemistry and Biomedicine, Department of Pharmaceutical Chemistry, Institute of Pharmacy, CMBI - Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0002-0427-4012
Stefan SalcherDepartment of Internal Medicine V, Hematology and Oncology, Tyrolean Cancer Research Institute (TKFI), Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0003-2391-6954

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present structure-activity relationship study investigates the development of novel chemosensitizers targeting therapy-resistant cancer stem cells (CSCs). We used 4'-((2-propyl-1

Indexed as

Drug Resistance, NeoplasmNeoplastic Stem CellsTelmisartanAngiotensin II Type 1 Receptor BlockersAnimalsAntineoplastic AgentsBenzimidazolesBenzoatesCell Line, TumorCell ProliferationFemaleHumansMaleMiceStructure-Activity RelationshipXenograft Model Antitumor AssaysAngiotensin II Type 1 Receptor BlockersAntineoplastic AgentsBenzimidazolesBenzoatesTelmisartan

Identifiers

PMID39693499
PMCPMC11726677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.